Waldencast plc, through its subsidiary Obagi Medical, has announced a collaboration with Next Health as part of the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. This partnership aims to drive real-world evidence for Obagi® saypha® MagIQ™ by leveraging Next Health's expertise in personalized wellness and advanced aesthetic treatments. Next Health will conduct a multi-site assessment of the injectable within its network, integrating data-driven protocols to evaluate both clinical efficacy and patient experience. The collaboration seeks to generate meaningful insights on the performance of saypha® MagIQ™ in wellness-focused environments, supporting holistic patient care and advancing innovation in the aesthetics and longevity sectors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waldencast plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9644069-en) on January 28, 2026, and is solely responsible for the information contained therein.